Tinostamustine Conditioning and Autologous Stem Cell

Stopped Sponsor decision based on adverse events limiting administration of higher doses required to achieve myeoblative conditioning necessary in this population

Conditions

• Multiple Myeloma in Relapse
• Multiple Myeloma Progression
• Multiple Myeloma With Failed Remission

Interventions

• DRUG: Tinostamustine
• PROCEDURE: Autologous Stem Cell Transplant (ASCT)

Sponsor

Mundipharma-EDO GmbH